Semaglutide for Type 2 Diabetes

Semaglutide addresses Type 2 diabetes through its action as a GLP-1 receptor agonist, mimicking the incretin hormone that naturally regulates blood glucose. When you inject semaglutide, it binds to GLP-1 receptors in pancreatic beta cells, triggering glucose-dependent insulin secretion—meaning insulin is only released when blood glucose levels are elevated.

This glucose-dependent mechanism significantly reduces hypoglycaemic risk compared to traditional diabetes medications. Semaglutide also suppresses glucagon release from pancreatic alpha cells when glucose levels are high, preventing excessive hepatic glucose production that characterises Type 2 diabetes.

Beyond glycaemic control, semaglutide dramatically slows gastric emptying, prolonging satiety and reducing post-meal glucose spikes. The peptide crosses the blood-brain barrier to activate GLP-1 receptors in hypothalamic appetite centres, leading to reduced caloric intake—crucial since most Type 2 diabetics struggle with weight management.

Semaglutide's extended half-life of approximately 165 hours allows once-weekly dosing, improving treatment adherence compared to daily medications. The peptide also demonstrates cardioprotective effects, reducing inflammatory markers and improving endothelial function—addressing the cardiovascular complications that plague diabetic patients.

Research indicates semaglutide may preserve pancreatic beta cell function, potentially slowing disease progression. Unlike insulin therapy, which can promote weight gain, semaglutide typically produces 10-15% body weight reduction whilst achieving superior glycaemic control with HbA1c reductions of 1.5-2.0%.

The SUSTAIN clinical trial programme provides robust evidence for semaglutide's efficacy in Type 2 diabetes. SUSTAIN-6, a cardiovascular outcomes trial involving 3,297 patients, demonstrated significant reductions in major adverse cardiovascular events alongside improved glycaemic control.

The SUSTAIN-1 trial showed semaglutide 1.0mg weekly achieved mean HbA1c reductions of 1.6% from baseline, with 72% of participants reaching target HbA1c levels below 7.0%. Concurrent weight loss averaged 4.5kg over 30 weeks, addressing the dual challenges of glycaemic control and obesity management.

SUSTAIN-2 compared semaglutide directly with sitagliptin in 1,231 patients inadequately controlled on metformin. Semaglutide demonstrated superior HbA1c reduction (1.5% vs 0.9%) and greater weight loss (4.3kg vs 1.9kg), establishing clear therapeutic advantages over existing DPP-4 inhibitors.

Real-world evidence from the SURE programme, analysing data from over 2,000 UK patients, confirmed clinical trial findings in routine practice. Patients achieved mean HbA1c reductions of 1.2% with average weight loss of 6.2kg over 12 months.

Emerging research suggests semaglutide may offer renoprotective benefits. Early evidence indicates reduced progression of diabetic nephropathy, though dedicated renal outcome trials are ongoing. Studies also demonstrate improved liver function markers in diabetic patients with concurrent non-alcoholic fatty liver disease.

Safety profiles remain favourable, with gastrointestinal side effects being the primary limitation. Research indicates these effects typically diminish with gradual dose escalation and usually resolve within 4-8 weeks of treatment initiation.

Begin semaglutide at 0.25mg once weekly for the first 4 weeks to establish tolerance, then increase to 0.5mg weekly. If additional glycaemic control is needed after 4 weeks at 0.5mg, escalate to the maintenance dose of 1.0mg weekly. Some patients may require the maximum dose of 2.0mg weekly for optimal control.

Inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipodystrophy. Administer on the same day each week, regardless of meals. If you miss a dose and it's within 5 days of the scheduled injection, take it immediately. If more than 5 days have passed, skip the missed dose.

For reconstitution guidance, consult our reconstitution guide and use our reconstitution calculator to ensure accurate dosing. Store reconstituted semaglutide refrigerated and use within 28 days.

Monitor blood glucose levels regularly, especially during dose escalation. Continue metformin therapy unless contraindicated—the combination provides synergistic benefits. Consider combining with SGLT-2 inhibitors for enhanced cardiovascular protection in high-risk patients.

Typical treatment cycles continue indefinitely as long-term diabetes management, with regular HbA1c monitoring every 3-6 months. Adjust doses based on glycaemic control and tolerability, working within the 0.25mg-2.0mg weekly range.

Be aware of gastrointestinal side effects during initiation—eating smaller, less fatty meals can help minimise nausea and vomiting.

Weeks 1-4: Initial 0.25mg dosing focuses on establishing tolerance. Expect mild appetite reduction and possible gastrointestinal effects (nausea, occasional vomiting). Blood glucose may begin trending downward, but significant changes aren't typical at this starter dose.

Weeks 5-8: Moving to 0.5mg weekly, you'll notice more pronounced appetite suppression and gradual weight loss (1-2kg). Morning glucose readings should improve, with post-meal spikes becoming less severe. Gastrointestinal effects typically diminish.

Weeks 9-16: At therapeutic doses (0.5-1.0mg), expect consistent blood glucose improvements. HbA1c should drop 0.5-1.0% from baseline. Weight loss accelerates to 3-5kg total, with improved satiety after smaller meals.

Months 4-6: Peak glycaemic benefits emerge with HbA1c reductions of 1.2-1.8%. Total weight loss typically reaches 5-8kg. Many patients achieve target HbA1c levels below 7.0% during this period.

Months 6-12: Sustained improvements in both glycaemic control and weight management. Research indicates 60-70% of patients maintain HbA1c targets with continued weight loss progression. Cardiovascular risk markers improve, with blood pressure and lipid profiles showing favourable changes.

Beyond 12 months: Long-term studies demonstrate maintained benefits with potential for further HbA1c improvements in some patients.